Executive and expert insights

From Strength to Strength: Unpacking Clinigen's Route to Success

Putting patient care at the heart of its mission, Clinigen’s unique approac...

[Webinar Recording] The Current State of the M&A Landscape

Are you considering M&A transactions as a potential exit strategy, step to ...

[Webinar Recording] The Anatomy of a successful IPO

On the 27th June, we spoke to an expert panel to discuss the how, when, wha...

Will Horizon successfully navigate the path to profit?

Currently one of the most successful life science companies in the country,...

Management to investors: the communicative conundrum

We have published our annual investor perception survey, confirming or disp...

All in the Delivery - Interview with Simon Newman, CSO, Ryboquin

Biotech and Money recently talked to Simon Newman, CSO of Ryboquin, about t...

Interview with Daniel Oliver, CEO of Capital Cell

Daniel Oliver, CEO of Capital Cell, recently took the time to grant us an i...

Patenting problems specific to the biotech and healthcare sector

This is the fourth and final article in our series that aims to provide tip...

Nine things we learned from Centauri CEO Mike Westby

Biotech and Money recently talked to Mike Westby, CEO of Centauri, about th...

Interview with Dr Sara Nunez-Garcia, Principal, Sofinnova Partners

Phacilitate's Investment for Advanced Therapies in partnership with Biotech...

What are the most important lessons to be learnt from the European immunotherapy and cell & gene therapy industries?

Phacilitate's Investment for Advanced Therapies in partnership with Biotech...

Bionure breaks the records raising more than 1M€

Highlights Capital Cell’s crowdfunding campaign - Bionure - overfunds with ...

United Data in the United Kingdom: Congenica Diagnoses a Bright Future for UK Life Science Technologies

Tom Weaver CEO Congenica Using data analytics and applying their software t...

Open Window in the West? Deciding whether to pursue a US IPO

By Kristian Wiggert Partner Covington & Burling LLP, London The recent stro...

The impact of other people’s IP on you

This is the third in a series of four articles which aim to provide tips fo...

Eyeing up the global aesthetics market

Here are some lessons we learned during a recent interview with CFO Alan Ol...

10 things we learned from Medicines Discovery Catapult CEO Chris Molloy

With a strong focus on the collaboration needed to solve problems common to...

How to make your IP investable

This is the second in a series of four articles which aim to provide tips f...

Of Mice and Men: Kymab scurries up the biologics ladder

Using the pioneering Kymouse human antibody expression platform, Kymab are ...

What is Medtech?

Medtech is a very broad sector – it covers any technology that can be used ...

How to make your IP investable

At the core of any biotech company is an innovative piece of science which ...

7 questions with Isobel Finnie, Europe and UK patent attorney, Haseltine Lake

Biotech and Money recently caught up with Europe and UK patent attorney Iso...

Cancer’s Achilles heel has been found

In March of this year, an article published in Science made waves throughou...

Advice for Startups

Do your homework! Startups need to ‘do their homework’ when selecting a cro...

Equity Crowdfunding and life sciences

Equity crowdfunding is particulary suited to life sciences

How does equity investment work?

What is equity crowdfunding? To any average member of Joe public, the word ...

Maxcyte: Aiming to be the very best in cell therapy

Having recently listed on the London Stock Exchange, CEO Doug Doerfler tell...

8 Things we learned from Orphan Drugs Industry Advisory and Intelligence founder Christian Girard

Christian Girard, expert in orphan drugs, competitive intelligence, in/out ...

Collaborations in novel, highly potent drug classes

Biotech and Money had the opportunity to speak with Alastair Smith, the CEO...

Top 4 Tips you need to prepare for Biotech IPO

Biotech companies have fared well recently in the IPO market in both the US...

Some highlights from Biotech and Money's recent MedTech Webinar

On September 15th we spoke exclusively to a panel of MedTech CEOs and inves...

9 things we learned from F2G CEO Ian Nicholson

Ian has over 25 years of international experience in management and transac...

Mironid: Giving off all the right signals

Comprising a team with expertise in both development and commercialisation,...

Biotech and Money Assembly and Awards Gala Dinner

On the evening of the 6th September, we welcomed over 220 of the UK’s most ...

Transforming the lives of airways disease patients

Vectura, fresh from its recent acquisition of SkyePharma, holds a unique, b...

Equity Crowdfunding: the new Venture Capital?

SyndicateRoom – formed in 2013 by Gonçalo de Vasconcelos (CEO) and Tom Brit...

Innovative Cancer Detection and the £11M IPO

Oncimmume, a leading UK early cancer detection company recently secured AI...

The Brexit Referendum Result

John Rountree, Managing Partner of Novasecta, a specialist pharmaceutical m...

9 Things we learned from Silence Therapeutics CEO Ali Mortazavi

Silence Therapeutics, formed in 1994 and with offices in London and Berlin,...

Syndicating for a £19M Series A financing

We find time with Paolo Paoletti, CEO of Kesios Therapeutics, a company wit...

Why Silence Therapeutics has the Midas touch

With interest in precision medicine growing, Silence’s ability to design, p...

Placements, Clinical Studies and the Utility of Parsortix

In this interview, we speak to Andrew Newland, the CEO of ANGLE plc, a comm...

Acquiring companies with realisable commercial tech

New acquisition vehicle Levrett comes online and immediately targets promis...

Enlarged Amryt Pharma joins AIM after reverse takeover

Joe Wiley, the CEO of Amryt Pharma, a speciality pharma company focused on ...

Securing follow-up funding investment

DefiniGEN CEO Marcus Yeo talks to Biotech and Money about his approach to s...

The role of the family office in life science investment

We have been sensing a growing trend of family office interest for getting ...

University of Oxford exosome spin-out excites investors

Fresh from their successful £10m seed fund raise from Oxford Science Innova...

The effect of brexit on venture investing

By James Shaw, Co-Founder, JAG Shaw Baker James has more than 15 years of i...

Brexit: implications for the life sciences sector

If the UK votes to exit the European Union (Brexit) following the referendu...

Brexit and the Implications for the Life Sciences Industry

With the UK's referendum on whether Britain should leave the European Union...

EU referendum: Leading UK scientists warn against consequences of Brexit

Leaders from across scientific disciplines tell MPs leaving EU would relega...

The Brexit Effect: A Blow To UK Life Science Leadership

In this article,Claire Skentelberylooks at the potential consequences for t...

Who will be debating the pros and cons of the Brexit?

Today marks exactly 3 weeks until Britain makes one of its biggest decision...

Brexit: Leaving the EU could trigger UK science patent law rejig

Some aspects of patent law of relevance to life sciences companies could co...

What would Brexit mean for the Pharma Industry?

The Conservatives' 2015 election manifesto committed to hold a referendum b...

A Breath of Fresh Air for the Global Respiratory Market

Dr. Jan-Anders Karlsson, CEO of Verona Pharma, shares company’s core focus ...

Should we stay or should we go?

The UK faces one of its biggest economic and political decisions in recent ...

Birmingham is becoming a leading location for Life Sciences

In an exclusive interview with Biotech and Money, Chris Yates,a prominent t...

Growing Life Sciences in Birmingham: The BioHub

James Wilkie, CEO of Birmingham Research Park,shines a spotlight on the Bir...

Medicxi launches GSK and J&J backed 210 million Euro Fund

Francesco de Rubertis, Co-Founder and Partner of Medicxi Ventures, talks to...

One Year on from IPO: Motif Bio’s Commercialisation Route

Graham Lumsden, CEO of Motif Bio, talks to Biotech and Money about the comm...

A Strategic Law Firm Central to the EU Tech & VC Ecosystem

Biotech and Money had the opportunity to talk with James Shaw, Co-Founder a...

Shield Therapeutics raises £32.5M in 2016 AIM Debut

Carl Sterritt, CEO of Shield Therapeutics, talks to Biotech and Money about...

A new era of collaboration: why Apollo Therapeutics succeed where other translational funding mechanisms have failed?

Ian Tomlinson, Chairman at Apollo Therapeutics, talks to Biotech and Money ...

Top Tips For Successful Private Fund Raise

Anker Lundemose, CEO of MISSION Therapeutics talks to Biotech and Money abo...

Investment Philosophies and Fundamental Trends

Biotech and Money had the opportunity to speak to Andy Smith CIO of Mann Bi...

Diurnal's £30M Fund Raising Success and AIM Listing

Biotech and Money had the opportunity to speak to MartinWhitaker CEO of Diu...

Biotechs and the City Spring, 31st March

On the evening of the 31st March, 'Biotechs and the City Spring' was the la...

Growth through commercialised tech and acquisitions

Biotech and Money had the opportunity to speak to Neil Campbell of Helomics...

Discovering new therapies to treat myocardial infarction

We recently spoke to Eddy Littler of Domainex about discovering new therapi...

Acquiring and developing a mid-stagE portfolio

We recently spoke to Denise Scots-Knightof MereoBioPharmaabout acquiring an...

Creating a substantial franchise in the allergy sector

We recently spoke to Manuel Llobet of Allergy Therapeutics about franchisin...

Biotech and Money London 2016 report: UK biotech bounces back

Ever since the collapse of British Biotech more than a decade ago, the UK l...

[ONES TO WATCH] Life Science showcases announced at Biotech and Money London 2016

At the 2nd annual Biotech and Money London conference, we’re all about givi...

[EBOOK] Get the Brand New Investor Interview with Mark Denham of Aviva Investors

Biotech and Money recently caught up with Mark Denham, Fund Manager and Hea...

Investor interview with Mark Barnett

Biotech and Money recently caught up with Mark Barnett, Head of UK Equities...

ADVANCED THERAPIES: NO LONGER JUST HYPE?

10-12 years ago everyone was talking about cell therapy and regenerative me...

6 things we learned from Manuel llobet, CEO of Allergy Therapeutics

Biotech and Money recently had the opportunity to speak to Manuel Llobet, C...

4 things I learned from Eddy Littler, CEO of Domainex

Biotech and Money recently had the opportunity to catch up with Eddy Little...

Announcing Brand New Agenda for 2nd Annual Biotech and Money London

What do the Global BD heads of GSK, AstraZeneca, rockstar investors like Si...

Masters of the Deal: Part 2 -

The following article is Part B of a study by the M&A Research Centre at Ca...

Transformational deal making: Oxford Biomedica

Given the recent announcement of Oxford Biomedica securing £50m loan fundin...

£25M Series C investment in the battle against Cancer

Dr John Beadle, CEO of PsiOxus Therapeutics outlines what the investment wi...

Oxford AHSN’s role in developing special networks

Prof. Gary Ford CBE, talks through what OAHSN is doing to break down tradit...

Spotting baby biotech unicorns

Valuing biotech assets, whether an early-stage private investment in a prec...

Francois Martelet, CEO and his aim for NetScientific Plc

3 months into his tenure as CEO of NetScientific, the vastly experienced in...

Five things I learned from Misti Ushio, Managing Director of Harris & Harris Group

Having previously worked as a researcher for Merck and at Columbia Universi...

Europe’s Largest Private Life Sciences Financing - Immunocore

Fresh from their record breaking £205m private finance raising, we talk to ...

Announcing 2nd Biotech and Money London - Partnership Opportunities now open

Last February the Biotech and Money London congress attracted over 280 of t...

Fundraising from one of the UK's leading investors

Newly appointed Chairman and CEO, Chris Yates discusses the potential of Ab...

Biotech and Money New York 2015 helps promote New York City as a centre for life science excellence

New York is a hotbed of life science innovation, yet the city has never qui...

Five things we learned from Rockefeller President Marc Tessier Lavigne

Biotech and Money recently caught up with Marc Tessier-Lavigne, president o...

Attracting investment from a leading EIS fund

We talk to CEO David Venables off the back of Synpromics securing £2.1m EIS...

What options do NYC start-ups have for funding their growth and development?

No biotech operation can thrive unless it has a well-stocked pipeline. Whet...

12 Strings to New York’s Biotech Bow

New York City authorities and life science giants are working to improve th...

Corporate Venture Capital: the answer for New York’s biotech start-ups?

New York City has nearly everything a city needs to become a biotech hub: h...

The Big Apple's 3 Ingredient Recipe for Success

1. Keeping Commercialisation in New York. There are obvious benefits in hol...

New York City as a life science powerhouse

New York has much to be proud of when it comes to life science research and...

6 Major Obstacles in New York’s Path to Life Science Superstardom

New York is a hotbed of life science innovation and – being the financial c...

GE Healthcare's innovation village nurtures early stage science

On 27th April Edwina Hart, Welsh Minister for Economy, Transport and Scienc...

Executive and expert insights